Cardiovascular profile of loratadine.

Cardiovascular profile of loratadine.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1999-08-12)

J A Hey, M Affrime, B Cobert, W Kreutner, F M Cuss

RÉSUMÉ

The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.

MATÉRIAUX

Référence du produit

Marque

Description du produit

PHR1376

Supelco

Loratadine, Pharmaceutical Secondary Standard; Certified Reference Material

L9664

Sigma-Aldrich

Loratadine, ≥98% (HPLC), powder

1370270

USP

Loratadine, United States Pharmacopeia (USP) Reference Standard

Y0000603

Loratadine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000688

Loratadine, European Pharmacopoeia (EP) Reference Standard